荧光原位杂交检测 中国就医指南

Fluorescence in Situ Hybridization (FISH) is not a disease but a highly sensitive molecular cytogenetic diagnostic technique widely used in hematology to detect specific chromosomal abnormalities—including deletions, duplications, translocations, and gene amplifications—in blood, bone marrow, or lymph node specimens. In the Department of Hematology, FISH plays a pivotal role in the diagnosis, risk stratification, and therapeutic monitoring of hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndromes (MDS), and lymphomas. Unlike conventional karyotyping, FISH can identify submicroscopic aberrations in interphase nuclei—making it especially valuable when metaphase cells are scarce or culture failure occurs. Pathogenetically, FISH detects structural or numerical chromosomal alterations that drive oncogenesis: for example, the t(9;22) BCR-ABL1 fusion in chronic myeloid leukemia (CML), del(13q) and del(11q) in CLL, del(5q) in MDS, or IGH translocations in MM. These abnormalities disrupt critical regulatory genes involved in cell cycle control, apoptosis, and differentiation, leading to clonal expansion of malignant hematopoietic cells. Epidemiologically, FISH testing is routinely performed across all age groups with suspected hematologic neoplasms; its utilization correlates strongly with incidence rates of underlying conditions—e.g., CLL peaks in adults over 65 (incidence ~4–5/100,000/year), while AML incidence rises sharply after age 60 (~20/100,000 in those >80). Risk factors for requiring FISH testing are thus tied to clinical indicators—not patient lifestyle—but include unexplained cytopenias, persistent lymphocytosis, abnormal peripheral smear findings, elevated serum free light chains, or radiographic evidence of lytic bone lesions. Importantly, FISH itself carries no inherent morbidity; however, delays or inaccuracies in FISH-based diagnosis may adversely impact quality of life by postponing targeted therapy, increasing anxiety during diagnostic uncertainty, or leading to inappropriate chemotherapy regimens. Timely, precise FISH results directly influence treatment selection—such as initiating tyrosine kinase inhibitors in BCR-ABL1+ cases or considering lenalidomide in del(5q) MDS—thereby improving symptom control, transfusion independence, progression-free survival, and overall functional status. Patients benefit from reduced hospitalizations, fewer adverse drug reactions, and enhanced psychosocial well-being when FISH-guided precision management is integrated early into their care pathway.

# 荧光原位杂交检测（FISH）治疗方案与费用明细（血液科）

一、非手术/保守检测方案

适用于初筛、复发监测、疗效评估及骨髓增殖性肿瘤、白血病、淋巴瘤等血液系统恶性肿瘤的分子分型。

• •基础FISH检测（单探针）：如BCR::ABL1、PML::RARA、IGH重排等，含标本处理、杂交、荧光显微镜阅片；费用：800–1,200元/项
• •多探针组合检测（3–5靶点）：用于复杂核型或MDS/AML风险分层；费用：2,200–3,500元/套
• •骨髓/外周血双样本同步检测：提升检出率；加收500元/第二样本

二、核心介入关联方案

FISH为诊断与分层工具，不属治疗手段，但直接指导靶向/化疗决策：

• •配合靶向治疗（如伊马替尼用于Ph+ ALL/CML）：需FISH确认融合基因；术前必查项目（含血常规、染色体核型、FISH）合计：1,800–2,600元

三、特殊复杂情形方案

• •耐药突变伴FISH动态监测（每周期复查）：1,500元/次
• •微小残留病（MRD）联合FISH+流式：4,800–6,200元/次
• •多发异常信号/隐匿性易位需高分辨FISH+NGS验证：7,500–9,800元/例

四、方案快速选择指南

✅ 初诊患者：选单探针FISH（800–1,200元），覆盖常见驱动异常； ✅ 高危/复发患者：选多探针组合（2,200–3,500元）+ MRD动态监测； ✅ 预算有限者：优先医保内项目（BCR::ABL1、PML::RARA等部分纳入乙类报销）。

> 注：所有费用依据北京协和医院、上海瑞金医院、广州中山一院2024年血液科FISH检测公示价执行，含试剂、人工、设备折旧及报告审核费。